Systematic Use of Telepsychiatry for Outpatients

Implementation and evaluation of video consultation in psychiatric outpatient treatment. The study will focus on patients' experiences regarding the use of VC. The study will also examine important aspects of the telepsychiatric consultation such as therapeutic alliance, consultation content, psychopathology and satisfaction levels compared to face-to-face consultations.

Study Overview

• Status: Completed
• Conditions: Depressive Disorder; Anxiety Disorders; Borderline Personality Disorder; Ptsd
• Intervention / Treatment: Other: Case management

• Study Type: Interventional
• Enrollment (Actual): 34
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Slagelse, Denmark
    • Psychiatric research unit, Region Zealand,

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• age > 18 years
• Danish-speaking.

Exclusion Criteria:

• Exclusion criteria included a diagnosis of schizophrenia or bipolar disorder, or suffering from substance abuse.
• Additionally, Participants in the VC group were excluded if they did not have a smartphone, tablet, laptop, or personal computer with a webcam.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Video group; Case management through video format	Other: Case management; Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
Active Comparator: In-person; Case management through in person format	Other: Case management; Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The demand for video consultation (VC) in clinical practice.	The demand for VC is evaluated by the percentage of included participants who chose to be in the VC group and the actual use of VC consultation sessions during the study period, including the number of missed appointments and the number of times VC sessions have been converted to telephone or in-person (IP) consultations.	One year
The implementation and integration of VC in clinical practice, as assessed by a checklist developed for the case managers (CM).	The following properties are used to evaluate the implementation and integration properties: type of technology patients use for VC sessions (Smartphone/tablet or personal computer/laptop); patients' physical location during VC session (Home or outdoor); the VC sessions confidentiality (Alone or with other persons); duration of VC session; the content of the VC sessions (supportive, therapy, medication management, crisis/acute or "mix" content) Descriptive statistics will be applied to evaluate the implementation and integration properties.	One year
Patients' experiences regarding the use of VC	Semistructured interviews have been conducted to evaluate participants' experience regarding the use of VC technology in clinical practice.	Two months
Patients' therapeutic alliance, assessed by working alliance inventory- client version (WAI-C)	Therapeutic alliance is evaluated with the mean change scores in the WAI-C questionnaire at baseline and posttreatment. Score ranging: from 12 to 84. Higher scores indicate a higher therapeutic alliance	Two months.
Patients' satisfaction, assessed by client satisfaction questionnaire 8 (CSQ-8)	Satisfaction is evaluated with the mean change scores in the CSQ-8 questionnaire at baseline and posttreatment. Score ranging: from 8 to 32. Higher scores indicate a higher satisfaction	Two months.
Patients' Symptom level, assessed by Symptom Checklist -10 (SCL-10)	Symptom level is evaluated with the mean change scores in the SCL-10 questionnaire at baseline and posttreatment. Score ranging: from 0 to 100. Lower score indicates lower psychological distress	Two months.
Patients' well-being, assessed by World Health Organisation- Five Well-Being Index (WHO-5)	Well-being level is evaluated with the mean change scores in the WHO-5 questionnaire at baseline and posttreatment. Score ranging: from 0 to 100. Higher scores indicate higher well-being	Two months.
Patients' function, assessed by Sheehan Disability Scale (SDS)	Functional impairment is evaluated with the mean change scores in the SDS questionnaire at baseline and posttreatment. Score ranging: from 0 to 30. lower scores indicate lower functional impairment	Two months.
Patient recovery, assessed by INSPIRE	Patient recovery is evaluated with the mean change scores in the INSPIRE questionnaire at baseline and posttreatment. Score ranging: from 0 to 100. A higher score indicates higher recovery	Two months.

Collaborators and Investigators

• Sponsor: Psychiatric Research Unit, Region Zealand, Denmark

Study record dates

Study Major Dates

• Study Start (Actual): April 21, 2021
• Primary Completion (Actual): April 26, 2022
• Study Completion (Actual): April 26, 2022

Study Registration Dates

• First Submitted: May 10, 2022
• First Submitted That Met QC Criteria: August 23, 2022
• First Posted (Actual): August 25, 2022

Study Record Updates

• Last Update Posted (Actual): March 31, 2023
• Last Update Submitted That Met QC Criteria: March 28, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Mood Disorders; Personality Disorders; Depressive Disorder; Disease; Anxiety Disorders; Borderline Personality Disorder
• Other Study ID Numbers: REG-003-2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No